sur OXURION (EBR:OXUR)
Oxurion 2025 Half-Year Results: Financial and Operational Analysis
On September 30, 2025, biopharmaceutical company Oxurion NV, listed on Euronext Brussels under the ticker OXUR, published its financial results for the first half of the year. This report covers the period ending June 30, 2025, and is available online in the investor section of the website. Leuven-based Oxurion focuses on majority stakes in European pharmaceutical contract manufacturers. The company aims to create an integrated group to support the healthcare sector.
It is important to note that this press release includes forward-looking statements that are subject to risks and uncertainties. The company undertakes no obligation to update these statements. Finally, Oxurion cautions against investing in digital assets, such as Bitcoin and Ethereum, due to their volatility and uncertain regulatory environment, which could affect investment performance.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de OXURION